Tomáš Tesař

1.7k total citations
49 papers, 440 citations indexed

About

Tomáš Tesař is a scholar working on Economics and Econometrics, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Tomáš Tesař has authored 49 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Economics and Econometrics, 17 papers in Surgery and 14 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Tomáš Tesař's work include Health Systems, Economic Evaluations, Quality of Life (25 papers), Pharmaceutical Economics and Policy (20 papers) and Peripheral Artery Disease Management (12 papers). Tomáš Tesař is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (25 papers), Pharmaceutical Economics and Policy (20 papers) and Peripheral Artery Disease Management (12 papers). Tomáš Tesař collaborates with scholars based in Slovakia, Hungary and Poland. Tomáš Tesař's co-authors include Martin Wawruch, Zoltán Kaló, Guenka Petrova, Paweł Kawalec, András Inotai, Ján Murín, Manoela Manova, András Harsányi, Ewa Stawowczyk and Maria Dimitrova and has published in prestigious journals such as Nutrients, Journal of Vascular Surgery and BioMed Research International.

In The Last Decade

Tomáš Tesař

47 papers receiving 432 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomáš Tesař Slovakia 14 249 89 70 68 62 49 440
Karen Van Nuys United States 10 128 0.5× 33 0.4× 61 0.9× 47 0.7× 19 0.3× 24 590
Andrea Belisari Italy 7 115 0.5× 56 0.6× 17 0.2× 29 0.4× 22 0.4× 23 462
Aisha Vadhariya United States 8 69 0.3× 25 0.3× 108 1.5× 23 0.3× 27 0.4× 32 279
Ansgar Hebborn Switzerland 8 129 0.5× 10 0.1× 42 0.6× 66 1.0× 21 0.3× 12 481
Ali Rahimi Iran 9 72 0.3× 93 1.0× 14 0.2× 41 0.6× 89 1.4× 25 445
Lisa A. Fulchino United States 8 160 0.6× 21 0.2× 37 0.5× 32 0.5× 13 0.2× 11 307
Joanna P. MacEwan United States 12 118 0.5× 16 0.2× 28 0.4× 22 0.3× 19 0.3× 53 391
M. Lebmeier United Kingdom 10 82 0.3× 53 0.6× 78 1.1× 45 0.7× 12 0.2× 21 408
L. Veronica Lee United States 11 261 1.0× 26 0.3× 27 0.4× 373 5.5× 112 1.8× 13 503
Genia Long United States 9 294 1.2× 93 1.0× 27 0.4× 6 0.1× 31 0.5× 19 391

Countries citing papers authored by Tomáš Tesař

Since Specialization
Citations

This map shows the geographic impact of Tomáš Tesař's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomáš Tesař with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomáš Tesař more than expected).

Fields of papers citing papers by Tomáš Tesař

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomáš Tesař. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomáš Tesař. The network helps show where Tomáš Tesař may publish in the future.

Co-authorship network of co-authors of Tomáš Tesař

This figure shows the co-authorship network connecting the top 25 collaborators of Tomáš Tesař. A scholar is included among the top collaborators of Tomáš Tesař based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomáš Tesař. Tomáš Tesař is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duborija-Kovačević, Nataša, Ariel Hammerman, Oleksandra Oleshchuk, et al.. (2025). EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia. Frontiers in Pharmacology. 16. 1629465–1629465.
2.
Wawruch, Martin, et al.. (2024). Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients. Frontiers in Pharmacology. 15. 1464689–1464689. 2 indexed citations
3.
Tesař, Tomáš, et al.. (2024). Pharmacist-led interventions for vascular surgery patients: a prospective study on reducing drug-related problems. BMC Health Services Research. 24(1). 1564–1564. 1 indexed citations
4.
5.
6.
Zemplényi, Antal, Konstantin Tachkov, Bertalan Németh, et al.. (2023). Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment. Frontiers in Public Health. 11. 1088121–1088121. 20 indexed citations
7.
Líšková, Silvia, et al.. (2023). Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia. Frontiers in Pharmacology. 14. 1097890–1097890. 2 indexed citations
8.
Kovács, Sándor, Zoltán Kaló, Katarzyna Kolasa, et al.. (2022). Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. Health Economics. 31(S1). 195–206. 8 indexed citations
9.
Kaló, Zoltán, et al.. (2021). Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. Cost Effectiveness and Resource Allocation. 19(1). 42–42. 6 indexed citations
10.
Németh, Bertalan, Wim Goettsch, Finn Børlum Kristensen, et al.. (2020). The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research. 20(4). 321–330. 14 indexed citations
11.
Ondušová, Daniela, et al.. (2020). Retrospective study assessing efficacy and safety of left atrial appendage occlusion. Bratislavské lekárske listy/Bratislava medical journal. 121(9). 609–618. 1 indexed citations
12.
Kaló, Zoltán, Antal Zemplényi, Maureen Rutten‐van Mölken, et al.. (2020). Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. Croatian Medical Journal. 61(3). 252–259. 6 indexed citations
13.
Tesař, Tomáš, et al.. (2020). Potential Cost-Savings From the Use of the Biosimilars in Slovakia. Frontiers in Public Health. 8. 431–431. 7 indexed citations
14.
Wawruch, Martin, et al.. (2020). Non-Adherence to Statin Treatment in Older Patients With Peripheral Arterial Disease Depending on Persistence Status. Journal of Vascular Surgery. 73(1). 344–344. 1 indexed citations
15.
Wawruch, Martin, et al.. (2020). Factors Associated with Reinitiation of Statin Treatment in Older Patients with Peripheral Arterial Disease. Drugs & Aging. 37(8). 595–604. 1 indexed citations
16.
Wawruch, Martin, Gejza Wimmer, Ján Murín, et al.. (2019). Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease. Drugs & Aging. 36(9). 863–873. 14 indexed citations
17.
Csanádi, Marcell, Zoltán Kaló, Leoš Fuksa, et al.. (2018). The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy and Technology. 7(3). 243–250. 15 indexed citations
18.
Kamusheva, Maria, Manoela Manova, Guenka Petrova, et al.. (2018). Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Frontiers in Pharmacology. 9. 795–795. 15 indexed citations
19.
Kawalec, Paweł, Tomáš Tesař, Manoela Manova, et al.. (2017). Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Frontiers in Pharmacology. 8. 892–892. 33 indexed citations
20.
Csanádi, Marcell, Guenka Petrova, Tomasz Bochenek, et al.. (2016). Mapping of The Biosimilar Drug Policy in 10 Central Eastern European Countries. Value in Health. 19(7). A504–A505. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Van Nuys Breakdown of academic impact, for papers by Andrea Belisari Breakdown of academic impact, for papers by Aisha Vadhariya Breakdown of academic impact, for papers by Ansgar Hebborn Breakdown of academic impact, for papers by Ali Rahimi Breakdown of academic impact, for papers by Lisa A. Fulchino Breakdown of academic impact, for papers by Joanna P. MacEwan Breakdown of academic impact, for papers by M. Lebmeier Breakdown of academic impact, for papers by L. Veronica Lee Breakdown of academic impact, for papers by Genia Long
Rankless by CCL
2026